Overcome bottlenecks in viral vector manufacturing

October 21, 2021

The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.

No Previous Videos

Up next
How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods

Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns ...